EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Assessment of baseline pretreatment factors and on‐treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin

Shi‐Chi Wen, Lung‐Chih Cheng, Jui‐Hung Hsu, Hsin‐Wen Lai, Pei‐Chen Shih, Chi‐Chang Tsai, Wu‐Hsien Kuo

Advances in Digestive Medicine · 2017

DOI: 10.1002/aid2.12004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Digestive Medicine, 2017. Verfasst von Shi‐Chi Wen und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pao-Chien hospital, Ping-Tung.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds Pegalated interferon (PEG‐IFN) combination with ribavirin (RBV) (PR) in accordance to response‐guide therapy (RGT) is a treatment option for chronic hepatitis C (CHC) in the past decade. Baseline host and viral factors and early viral kinetics are important determinants for patient using combination therapy.

Aims

We aimed to investigate the effects of host and viral factors on sustained virus response (SVR). We researched the possible predictors of an SVR.

Methods

We retrospectively analyzed a total of 158 CHC patients who had been treated with a PR dual therapy. Clinical parameters and virological responses were analyzed for their relationship with SVR.

Results

The overall SVR rate was 71.5% (113/158). Factors associated with an SVR were ALT levels > 3xULN, non‐AST/ALT > 1, non‐genotype 1 and non‐cirrhosis. Non‐genotype 1 (OR: 3.154; 95% CI: 1.309‐7.601; P = 0.010), and non‐cirrhosis (OR: 2.696; 95% CI: 1.045‐6.956; P = 0.004) were the predictors of an SVR. An SVR significantly increased in patients with an RVR and significantly reduced in patients with cEVR, pEVR, null response and relapse. In addition, an RVR was a powerful independent predictor of an SVR (OR: 38.263; 95% CI: 10.184‐143.757; P = 0.000). The positive predictive value (PPV) of an RVR on SVR was 92.2% (94/102).

Conclusions

Non‐cirrhosis, non‐genotype 1 and achievement of an RVR are independent predictors of SVR. A 4 week RVR is the best predictor of an SVR in CHC patients with a PR dual treatment. An RVR predicts treatment success early. Copyright © 2016, The Gastroenterological Society of Taiwan, The Digestive Endoscopy Society of Taiwan and Taiwan Association for the Study of the Liver.

Förderung

  • Pao-Chien hospital, Ping-Tung

Zitieren

APA

Wen, S., Cheng, L., Hsu, J., Lai, H., Shih, P., Tsai, C., & Kuo, W. (2017). Assessment of baseline pretreatment factors and on‐treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Advances in Digestive Medicine. https://doi.org/10.1002/aid2.12004

Vancouver

Wen S, Cheng L, Hsu J, Lai H, Shih P, Tsai C, et al. Assessment of baseline pretreatment factors and on‐treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Advances in Digestive Medicine. 2017. doi:10.1002/aid2.12004

BibTeX
@article{Wen2017,
  author = {Wen, Shi‐Chi and Cheng, Lung‐Chih and Hsu, Jui‐Hung and Lai, Hsin‐Wen and Shih, Pei‐Chen and Tsai, Chi‐Chang and Kuo, Wu‐Hsien},
  title = {Assessment of baseline pretreatment factors and on‐treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin},
  journal = {Advances in Digestive Medicine},
  year = {2017},
  doi = {10.1002/aid2.12004}
}
Kostenlos starten →